BioCryst Pharmaceuticals Files 8-K on Financial Results
Ticker: BCRX · Form: 8-K · Filed: Feb 26, 2024 · CIK: 882796
Sentiment: neutral
Topics: financial-condition, regulation-fd, corporate-filing
TL;DR
**BioCryst Pharmaceuticals just dropped an 8-K on their financials, so keep an eye out for details on their performance.**
AI Summary
BioCryst Pharmaceuticals, Inc. filed an 8-K on February 26, 2024, to report its financial condition and results of operations. The filing also included a Regulation FD Disclosure and information regarding financial statements and exhibits. The company, based in Durham, North Carolina, operates in the biological products industry.
Why It Matters
This filing provides investors with current financial information, which is crucial for evaluating BioCryst Pharmaceuticals' performance and making informed investment decisions.
Risk Assessment
Risk Level: low — This is a routine filing for reporting financial results and does not inherently indicate new risks.
Key Players & Entities
- BioCryst Pharmaceuticals, Inc. (company) — Registrant
- Durham, North Carolina (company) — Business address location
- February 26, 2024 (date) — Date of earliest event reported and filing date
- 000-23186 (company) — Commission File Number
- 62-1413174 (company) — I.R.S. Employer Identification No.
FAQ
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing was February 26, 2024.
What items of information were included in this 8-K filing?
The 8-K filing included information on Results of Operations and Financial Condition, Regulation FD Disclosure, and Financial Statements and Exhibits.
What is the business address of BioCryst Pharmaceuticals, Inc. as stated in the filing?
The business address of BioCryst Pharmaceuticals, Inc. is 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703.
What is the Commission File Number for BioCryst Pharmaceuticals, Inc.?
The Commission File Number for BioCryst Pharmaceuticals, Inc. is 000-23186.
What is the Standard Industrial Classification (SIC) for BioCryst Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) for BioCryst Pharmaceuticals, Inc. is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
Filing Stats: 571 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-02-26 07:05:56
Filing Documents
- f8k_022624.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 88KB
- 0001171843-24-000967.txt ( ) — 308KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_022624_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On February 26, 2024, BioCryst Pharmaceuticals, Inc. (the "Company") issued a press release announcing recent corporate developments and its financial results for the fourth quarter and full year ended December 31, 2023, which also referenced a conference call and webcast to discuss these recent corporate developments and financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. The information furnished on Exhibit 99.1 is incorporated by reference under this Item 7.01 as if fully set forth herein. The information in this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated February 26, 2024 entitled "BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioCryst Pharmaceuticals, Inc. Date: February 26, 2024 By: /s/ Alane Barnes Alane Barnes Chief Legal Officer